ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Analysts Trim Targets Across Sectors

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Consensus target prices fell on several large-cap names this week. The moves are small but broad, spanning consumer staples, industrials and financials.

McCormick saw its average analyst target price dip to $54.46 from $54.85. The spice maker already faces ORTEX Index Rebalance Radar pressure. McCormick carries a 77% probability of deletion from the MSCI World in the November review, with $735M of forced selling flagged over 4.4 days of volume. That combination of falling targets and index exit risk makes it one to watch.

Deckers Outdoor also took a target cut, with consensus slipping to $98.19 from $99.95. Short interest sits at 8.7% of free float. That is not extreme, but it is elevated for a consumer discretionary name.

Bloom Energy attracted multiple rating changes. The consensus buy count shifted from one to two, nudging sentiment slightly more positive. Analysts lifted the average target to $284.77 from $284.58. The move is marginal but the direction is positive after a prolonged period of mixed signals.

On the upside, Merck received a target price increase, lifting consensus to $159.76 from $158.56. SLB also gained, moving to $62.34. Coinbase target edged up to $213.55 as crypto sentiment stays firm.

Honeywell and American Express both saw marginal target reductions, consistent with the cautious tone across cyclicals heading into earnings season.

Stocks in this article

How this article was generated

Generated
25 Oct 2026, 08:20
Prompt version
v1.0
Data sources
Analyst consensusAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.